Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

As of 11 a.m. ET, shares of Novo Nordisk (NYSE: NVO) are down 4.2%, and Hims & Hers Health (NYSE: HIMS) stock is getting walloped for a 5.8% loss. In contrast, shares of Viking Therapeutics ...

Novo Nordisk (NVO) announced Friday that its popular ... at a higher dose of 7.2 mg in a late-stage trial. Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that ...

Novo Nordisk's GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications.Seana Smith and Brad Smith ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) fell 3.6% on Friday after the U.S. Department of Health and Human Services (HHS) announced that Ozempic and Wegovy are among 15 medications ...

After Novo Nordisk (NVO) reported results from its Phase ... BofA analyst Sachin Jain called the data “a double edged sword.” The high-dose results lift the efficacy of semaglutide as ...

After Novo Nordisk (NVO) reported results from its Phase ... The firm, which believes the data highlights the potential superiority of Viking’s dual GLP-1/GIP receptor agonist VK2735 over ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.

A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 ...